Diabetes Mellitus: chronic complications by Zolotarova T.V. et al.
Diabetes Mellitus: 
chronic 
complications 
Assistant of Department Tetiana V. Zolotarova 
Candidate of Medicine, Associate Professor of 
Department Ella V. Karnaukh 
Head of the Department of Propaedeutics of 
Internal Medicine and Physical Rehabilitation, 
Candidate of Medicine 
Mariia S. Brynza 
2020 
DM: Complications 
A summary of the features of diabetes-related 
complications includes the following: 
 Duration and degree of hyperglycemia correlate 
with complications 
 Intensive glycemic control is beneficial in all forms 
of DM 
 Blood pressure control is critical, especially in 
type 2 DM 
 Survival in patients with type 1 DM is improving, 
and diabetes-related complications are declining 
 Not all individuals with diabetes develop diabetes-
related complications. 
DM: Complications 
Four theories, which are not mutually exclusive, on how hyperglycemia might 
lead to the chronic complications of DM include the following pathways. 
 (1) Increased intracellular glucose leads to the formation of advanced 
glycosylation end products, which bind to a cell surface receptor, via the 
nonenzymatic glycosylation of intra- and extracellular proteins, leading to 
cross-linking of proteins, accelerated atherosclerosis, glomerular 
dysfunction, endothelial dysfunction, and altered extracellular matrix 
composition 
 (2) Hyperglycemia increases glucose metabolism via the sorbitol pathway 
related to the enzyme aldose reductase. 
 (3) Hyperglycemia increases the formation of diacylglycerol, leading to 
activation of protein kinase C, which alters the transcription of genes for 
fibronectin, type IV collagen, contractile proteins, and extracellular matrix 
proteins in endothelial cells and neurons 
 (4) Hyperglycemia increases the flux through the hexosamine pathway, 
which generates fructose-6-phosphate, a substrate for O-linked 
glycosylation and proteoglycan production, leading to altered function by 
glycosylation of proteins such as endothelial nitric oxide synthase or by 
changes in gene expression of transforming growth factor β (TGF-β) or 
plasminogen activator inhibitor-1. 
DM : Complications 
 Diabetes-related complications affect many organ 
systems and are responsible for the majority of 
morbidity and mortality associated with the 
disease 
 Diabetes-related complications can be divided 
into vascular and nonvascular complications and 
are similar for type 1 and type 2 DM 
 The vascular complications of DM are 
further subdivided into microvascular 
(retinopathy, neuropathy, nephropathy) and 
macrovascular complications (coronary heart 
disease, peripheral arterial disease [PAD], 
cerebrovascular disease). 
Diabetic retinopathy 
 DM is the leading cause of blindness 
between the ages of 20 and 74 in the 
United State 
 Diabetic retinopathy is classified into two 
stages: nonproliferative and proliferative 
Diabetic retinopathy 
https://drlleung.com/blog/f/how-does-diabetic-retinopathy-cause-vision-loss 
Diabetic retinopathy: Nonproliferative 
Diabetic Retinopathy (NPDR) 
NDPR occurs when the retinal blood vessels start to leak, causing blood or fluid to seep into 
the retina. The retina becomes thick and swollen and does not work correctly. If the leaking 
happens in the macula, (the central part of the retina), vision will be blurred. If the leaks occur 
in the periphery of the retina, there may be no impact to vision. 
 Nonproliferative retinopathy is found in many individuals who have had DM for >20 years 
https://www.retinamd.com/diseases-and-treatments/retinal-conditions-and-diseases/diabetic-retinopathy/ 
Diabetic retinopathy: Proliferative 
Diabetic Retinopathy (PDR) 
 PDR occurs when the retinal blood vessels close, cutting off nutrition to the retinal tissue. 
The appearance of neovascularization in response to retinal hypoxemia is the hallmark of 
proliferative diabetic retinopathy 
 These newly formed vessels appear near the optic nerve and/or macula and rupture easily, 
leading to vitreous hemorrhage, fibrosis, and ultimately retinal detachment. 
https://www.retinamd.com/diseases-and-treatments/retinal-conditions-and-diseases/diabetic-retinopathy/ 
Diabetic retinopathy: 
TREATMENT 
The most effective therapy for diabetic 
retinopathy is prevention!!! 
 Intensive glycemic and blood pressure control will 
delay the development or slow the progression of 
retinopathy in individuals with either type 1 or 
type 2 D 
 Regular, comprehensive eye examinations are 
essential for all individuals with DM 
 Proliferative retinopathy is usually treated with 
panretinal laser photocoagulation, whereas 
macular edema is treated with focal laser 
photocoagulation and anti–vascular endothelial 
growth factor therapy (ocular injection) 
Outpatient Glucose Targets for 
Nonpregnant Adults 
Parameter Treatment Goal 
 A1C, % 
Individualize on the basis of age, 
comorbidities, duration of disease, and 
hypoglycemia risk: 
• In general, ≤6.5 for most* 
• Closer to normal for healthy 
• Less stringent for “less healthy” 
 FPG, mg/dL <110 (6.1 mmol/l) 
 2-Hour PPG, mg/dL <140 (7.8 mmol/l) 
10 
FPG = fasting plasma glucose; PPG = postprandial glucose. 
*Provided target can be safely achieved. 
Diabetic nephropathy 
Diabetic nephropathy is 
the leading cause of 
chronic kidney disease 
(CKD), ESRD, and CKD 
requiring renal 
replacement therapy 
Diabetic nephropathy 
 The mechanisms by which chronic 
hyperglycemia leads to diabetic nephropathy, 
although incompletely defined, involve the effects 
of soluble factors (growth factors, angiotensin II, 
endothelin, advanced glycation end products 
[AGEs]), hemodynamic alterations in the renal 
microcirculation (glomerular hyperfiltration or 
hyperperfusion, increased glomerular capillary 
pressure), and structural changes in the 
glomerulus (increased extracellular matrix, 
basement membrane thickening, mesangial 
expansion, fibrosis) 
https://upload.wikimedia.org/wikipedia/commons/6/69/Renal_corpuscle-en.svg 
Diabetic nephropathy 
https://www.researchgate.net/figure/Characteristic-histological-features-of-diabetic-
nephropathy-Notes-In-advanced-diabetic_fig1_267731120 
Diabetic nephropathy 
 Glomerular hyperperfusion and renal hypertrophy occur in 
the first years after the onset of DM and are associated with 
an increase of the glomerular filtration rate (GFR) 
 During the first 5 years of DM, thickening of the glomerular 
basement membrane, glomerular hypertrophy, and mesangial 
volume expansion occur as the GFR returns to normal 
 After 5–10 years of type 1 DM, many individuals begin to 
excrete small amounts of albumin in the urine (persistent 
albuminuria (≥300 mg/24 h)) 
 Once macroalbuminuria is present, there is a steady 
decline in GFR, and ~50% of individuals reach ESRD 
in 7–10 years 
 Once macroalbuminuria develops, blood pressure rises 
slightly and the pathologic changes are likely irreversible 
 The serum creatinine to estimate GFR should also be 
performed 
Diabetic nephropathy: 
TREATMENT 
The optimal therapy for diabetic 
nephropathy is prevention by 
control of glycemia 
 
Interventions effective in slowing progression 
of albuminuria include  
 (1) improved glycemic control 
 (2) strict blood pressure control 
 (3) administration of an ACE inhibitor or 
ARB 
 Dyslipidemia should also be treated 
Diabetic neuropathy 
 Diabetic neuropathy occurs in ~50% of individuals 
with long-standing type 1 and type 2 DM 
 It may manifest as polyneuropathy, 
mononeuropathy,and/or autonomic neuropathy 
 It most frequently presents with distal sensory 
loss and pain, but up to 50% of patients do not 
have symptoms of neuropathy 
 Symptoms may include a sensation of numbness, 
tingling, sharpness, or burning that begins in the 
feet and spreads proximally 
Diabetic neuropathy: TREATMENT 
 Chronic, painful diabetic neuropathy is 
difficult to treat but may respond to 
duloxetine, amitriptyline, gabapentin, 
valproate, pregabalin, or opioids. 
Diabetic neuropathy: TREATMENT 
https://www.pharmacytimes.com/publications/issue/2008/2008-10/2008-10-8712 
DM and Coronary artery 
disease  
 Coronary artery disease (CAD) is a major 
determinant of the long-term prognosis among 
patients with DM 
 Amongst adults with DM there is a prevalence of 75% 
to 85% of hypertension, 70% to 80% for elevated 
LDL, and 60% to 70% for obesity 
 CAD is the main cause of death in both type 1 and 
type 2 DM,  and DM is associated with a 2 to 4-fold 
increased mortality risk from heart disease 
 The American Heart Association has designated DM 
as a “CHD risk equivalent,” and type 2 DM patients 
without a prior myocardial infarction (MI) have a 
similar risk for coronary artery–related events as 
nondiabetic individuals who have had a prior MI 
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4672945/#:~:text=Coronary%20artery%20disease%20(CAD)%20is,worse%20overall%20prognosis%20with%20CAD. 
DM and CAD 
http://www.lifelinehealthcarebd.org/Heart-Diseases-129 
DM and CAD 
 Risk factors for macrovascular disease in 
diabetic individuals include dyslipidemia, 
hypertension, obesity, reduced physical 
activity, and cigarette smoking 
 Additional risk factors more prevalent in the 
diabetic population include  
microalbuminuria, macroalbuminuria, an 
elevation of serum creatinine, abnormal 
platelet function and endothelial dysfunction 
 Diagnosis of CAD should be done according 
current guidelines for CAD management 
Harrison's Principles of Internal Medicine, 20ec 
DM and CAD: Treatment 
 Aggressive cardiovascular risk 
modification in all individuals with DM 
and glycemic control should be 
individualized 
 In patients with known CAD and type 2 
DM, an ACE inhibitor (or ARB), a statin, 
and acetylsalicylic acid (ASA; aspirin) 
should be considered 
Harrison's Principles of Internal Medicine, 20ec 
DM and CAD: Treatment 
 In general, the treatment of coronary disease is not 
different in the diabetic individual (see 2019 
Guidelines on Chronic Coronary Syndromes 
https://www.escardio.org/Guidelines/Clinical-Practice-
Guidelines/Chronic-Coronary-Syndromes) 
 Revascularization procedures for CAD, including 
percutaneous coronary interventions (PCI) and 
coronary artery bypass grafting (CABG), may be less 
efficacious in the diabetic individual 
 Initial success rates of PCI in diabetic individuals are 
similar to those in the nondiabetic population, but 
diabetic patients have higher rates of restenosis and 
lower long-term patency and survival rates in older 
studies 
Harrison's Principles of Internal Medicine, 20ec 
LOWER EXTREMITY 
COMPLICATIONS 
 DM is the leading cause of nontraumatic 
lower extremity amputation in the United 
States 
 Foot ulcers and infections are also a major 
source of morbidity in individuals with DM 
 The reasons for the increased incidence of 
these disorders in DM involve the 
interaction of several pathogenic factors: 
neuropathy, abnormal foot biomechanics, 
PAD, and poor wound healing. 
Diabetic foot 
 https://www.vitad.org/tiki-
index.php?page=Diabetic%20Foot%20Ulc
er%203.2%20X%20or%203.6%20X%20mo
re%20likely%20if%20low%20vitamin%20D
%20%E2%80%93%20meta-
analyses%202019 
https://www.vitad.org/tiki-
index.php?page=Diabetic%20Foot%20Ulcer%203.2%20X%20or%203.6%20X%20more%20likel
y%20if%20low%20vitamin%20D%20%E2%80%93%20meta-analyses%202019 
An 85-year-old 
woman with Wagner 
grade 5 diabetic foot 
ulcer. She had type 2 
DM for 25 years; 75 
sessions of HBOT 
were applied over 3 
months. Serial clinical 
photos throughout 
HBOT (hyperbaric 
oxygen therapy) and 
the final result 
DOI: 10.1007/s00264-008-0623-y 
CASE STUDY 1.3. 
TYPE II DIABETIC FOOT 
 Type of Wound: Diabetic Foot Ulcer 
 Patient: 61 year-old male 
 A 61 year-old male, with a medical history notable for Type II 
diabetes, hypertension and hypercholesterolemia, presented 
with an ulcer on the lateral aspect of the left midfoot 
 On physical exam, there was an abscess which tracked 
medially across the entire plantar midfoot (Image #1-2) 
 The patient was admitted emergently for antibiosis, and the 
wound was debrided and abscess drained in the OR 
(Image#3) 
 The right lower extremity was subsequently revascularized 
 The tunneled track was filled with the single layer Integra™ 
Matrix and covered and fixated with the Integra™ Bilayer 
Matrix 31 days later (Image #4) 
DIABETIC SKIN ULCER 
INTEGRA™ MATRIX WOUND DRESSING • INTEGRA™ BILAYER MATRIX WOUND DRESSING 
CASE STUDY 2.3. 
DIABETIC SKIN ULCER 
INTEGRA™ MATRIX WOUND DRESSING • INTEGRA™ BILAYER MATRIX WOUND DRESSING 
CASE STUDY 3.3. 
 The graft was completely integrated by post-op day 50 (images #5 and 
6), with complete closure at post-op day 113 (Image #7 ) 
 The patient was fitted for a custom-molded brace for ambulation 
 Wound closure has been maintained without incident for 2 years 
(images #8 and 9) 
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